GDRX Alert: Johnson Fistel Launches Investigation into GoodRx; Investors Suffering Losses Encouraged to Contact the Firm

News provided by

Dec 11, 2020, 19:00 ET

SAN DIEGO, Dec. 11, 2020 /PRNewswire/ --Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX) for potential violations of federal securities laws.

On September 23, 2020, GoodRx sold about 34.6 million shares of stock in its initial public stock offering (the "IPO") at $33.00 a share, raising approximately $1.1 billion in new capital. Post-IPO, GoodRx stock traded at a high of $64.22; on December 10, 2020, the stock closed at $38.92.

Specifically, Johnson Fistel's investigation seeks to determine whether the Company's filings with the U.S. Securities and Exchange Commission in connection with its September 2020 IPO contained untrue statements of material facts or omitted to state other facts necessary to make the statements made therein not misleading concerning the Company's business, and operations.

If you have information that could assist in this investigation, or if you are a GoodRx shareholder and are interested in learning more about the investigation, please contact Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[Click here to join this action]

SOURCE Johnson Fistel, LLP